Answers are grounded in this paper and cite their sources.
PF-07284892-targeted therapy combinations overcame bypass-signaling-mediated resistance in a clinical setting in which neither component was active on its own. This provides proof of concept of the utility of SHP2 inhibitors in overcoming resistance to diverse targeted therapies and provides a paradigm for accelerated testing of novel drug combinations early in clinical development. See related commentary by Hernando-Calvo and Garralda, p. 1762. This article is highlighted in the In This Issue feature, p. 1749.
No takes yet. Share an insight, caveat, or question.
Drilon et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: